

ESC Highlights 2022

Recorded Live on:



September 12
7:30 – 9:00 pm EDT



Developed by:



ESC 2022 Highlights: Recorded Webcast



CO-CHAIRS

Milan Gupta,
MD, FRCPC, FCCS, CPC(HC)
Assistant Professor, Department
of Medicine, University of Toronto
Medical Director, Canadian
Collaborative Research Network
Brampton, ON



CO-CHAIRS

Narendra Singh,
MD, FRCPC, FCCS, FACC, FAHA
Director, NSC Cardiology
Clinical Assistant Professor,
Medical College of Georgia at
Augusta University and Mercer
University
Atlanta, GA



CO-CHAIRS

Michelle O'Donoghue,
MD, MPH
Associate Professor, Harvard
Medical School
Cardiovascular Medicine,
Boston, MA

This program will cover the key clinical trial findings and their implications from ESC 2022. This program is intended for cardiovascular specialists and primary care physicians from across Canada.

Discussion Topics:

- DELIVER** – Does dapagliflozin improve outcomes in HFpEF?
 - PERSPECTIVE** – Does sacubitril/valsartan affect cognitive function in heart failure?
 - PACIFIC Trials** – What is the role of new factor Xa inhibitors in stroke and ACS?
 - FOURIER OLE** – What are the long-term safety data for PCSK9 inhibitors?
 - ALL-HEART** – Does allopurinol improve cardiovascular outcomes?
 - SECURE** – Is there a role for a polypill in secondary prevention?
- And more!**

Learning Objectives:

Following participation in this program, participants will be able to:

- Identify the clinical implications of the new data presented at ESC 2022
- Examine where the data presented may impact clinical practice guidelines
- Apply the latest evidence-based strategies in clinical practice



This program was developed by CCRN and received an unrestricted educational grant from AstraZeneca, Amgen, Bayer, and Novartis



Watch the recording on MDLearn [Here](#)



www.mdlearn.com > MDWatch